Form 4: OCUL CMO Granted 40K RSUs, 122K Stock Options

Ocular Therapeutix's Chief Medical Officer, Nadia Waheed, received grants of 40,363 restricted stock units and 122,923 stock options as part of her compensation.

Summary

• Nadia Waheed, Chief Medical Officer of Ocular Therapeutix, Inc. (OCUL), was granted 40,363 restricted stock units (RSUs) and 122,923 stock options on August 12, 2025.
• The RSUs were issued under the 2021 Stock Incentive Plan and each RSU represents a right to receive one share of the company's common stock.
• RSUs will vest over three years in equal annual installments, with the first vesting date beginning on February 11, 2026, contingent on continued service.
• The stock options have an exercise price of $12.48 per share and are set to expire on August 11, 2035.
• Stock options will vest with 7/48 of the shares on September 11, 2025, and 1/48 of the shares vesting monthly thereafter through February 11, 2029.
• Following these transactions, Nadia Waheed beneficially owns 247,168 shares of common stock and 122,923 stock options.

Sentiment

Score: 7

Explanation: The filing reports a standard executive compensation grant, which is a positive for executive retention and alignment with shareholder interests, indicating stability in management incentives.

Positives

• Grants of restricted stock units and stock options serve as incentives for the Chief Medical Officer, aligning her interests with long-term shareholder value.
• The vesting schedules for both equity grants promote the retention of key executive talent over several years.

Future Outlook

The vesting schedules for both the restricted stock units and stock options extend several years into the future, indicating an expectation of continued service from the Chief Medical Officer and a long-term incentive structure.

Industry Context

This transaction represents a routine executive compensation event, common across the biotechnology and pharmaceutical industries, where equity grants are frequently used to attract, retain, and incentivize key scientific and medical leadership.

Stakeholder Impact

• Shareholders: The grants dilute existing shareholder equity over time as RSUs vest and options are exercised, but also align executive incentives with long-term company performance.
• Employees: May signal stability in executive leadership and a commitment to equity-based compensation.
• Executive (Nadia Waheed): Directly benefits from the equity grants, providing a significant incentive for continued service and performance.

Next Steps

• Continued vesting of 40,363 restricted stock units in equal annual installments beginning February 11, 2026.
• Continued vesting of 122,923 stock options, with 7/48 vesting on September 11, 2025, and 1/48 monthly thereafter through February 11, 2029.

Key Dates

Keywords

Ocular Therapeutix, OCUL, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Nadia Waheed, Chief Medical Officer, Equity Grant